Literature DB >> 533260

Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis.

E L Francke, G B Appel, H C Neu.   

Abstract

The pharmacokinetic properties of piperacillin, a piperazine derivative of ampicillin, were determined in seven patients with creatinine clearances less than 7 ml/min who were undergoing chronic, intermittent hemodialysis. A two-compartment linear model was used to analyze the data. Mean elimination half-life was 1.26 +/- 0.1 h; the mean elimination constant was 0.95 +/- 0.08 h-1; the mean volume of distribution was 0.16 +/- 0.02 liters/kg of body weight; the mean volume of the central compartment was 0.10 +/- 0.01 liters/kg of body weight; and the mean clearance was 0.09 +/- 0.01 liters/h per kg of body weight. Mean elimination half-life while off dialysis of 2.1 h.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 533260      PMCID: PMC352954          DOI: 10.1128/AAC.16.6.788

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  The penicillins. II. Overview of pharmacology, toxicology, and clinical use.

Authors:  H C Neu
Journal:  N Y State J Med       Date:  1977-05

2.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

3.  Pharmacodynamics of carbenicillin in hepatic and renal failure.

Authors:  T A Hoffman; R Cestero; W E Bullock
Journal:  Ann Intern Med       Date:  1970-08       Impact factor: 25.391

4.  Generalized solution to linear, to-compartment, open model for drug distribution.

Authors:  K B Bischoff; R L Dedrick
Journal:  J Theor Biol       Date:  1970-10       Impact factor: 2.691

5.  Pharmacokinetics of piperacillin following intravenous administration.

Authors:  M A Evans; P Wilson; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

6.  Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

7.  In vitro activity of piperacillin, a new semisynthetic penicillin with an unusually broad spectrum of activity.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

8.  Ticarcillin for treatment of serious infections with gram-negative bacteria.

Authors:  M G Parry; H C Neu
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

9.  Kinetics of mezlocillin and carbenicillin.

Authors:  S J Pancoast; H C Neu
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

10.  Piperacillin kinetics.

Authors:  V K Batra; J A Morrison; K C Lasseter; V A Joy
Journal:  Clin Pharmacol Ther       Date:  1979-07       Impact factor: 6.875

View more
  10 in total

Review 1.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

2.  Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration.

Authors:  Kook-Hwan Oh; Chiweon Kim; Hankyu Lee; Hajeong Lee; Ji Yong Jung; Nam Joong Kim; Kyung-Sang Yu; Kwang-Hee Shin; In-Jin Jang; Curie Ahn
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

3.  Pharmacokinetics of piperacillin in subjects with various degrees of renal function.

Authors:  P G Welling; W A Craig; R W Bundtzen; F W Kwok; A U Gerber; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

Review 4.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

5.  Optimal design of perturbations for individual two-compartment pharmacokinetic analysis.

Authors:  Matthew S Shotwell; Minchun Zhou; William H Fissell
Journal:  J Biopharm Stat       Date:  2015-08-06       Impact factor: 1.051

6.  Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis.

Authors:  J A Giron; B R Meyers; S Z Hirschman; E Srulevitch
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

7.  Biliary concentrations of piperacillin in patients undergoing cholecystectomy.

Authors:  J A Giron; B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

Review 8.  Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; D M Richards; R N Brogden; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

9.  Piperacillin pharmacokinetics in subjects with chronic renal failure.

Authors:  M I Thompson; M E Russo; J M Matsen; E Atkin-Thor
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

Review 10.  Piperacillin-tazobactam as alternative to carbapenems for ICU patients.

Authors:  Benoit Pilmis; Vincent Jullien; Alexis Tabah; Jean-Ralph Zahar; Christian Brun-Buisson
Journal:  Ann Intensive Care       Date:  2017-11-10       Impact factor: 6.925

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.